Market Tracker

05/27 6:45pm ET

Sarepta Therapeutics Inc (NASDAQ:SRPT)

21.19
Delayed Data
As of May 27
 -1.01 / -4.55%
Today’s Change
8.00
Today|||52-Week Range
41.97
-45.08%
Year-to-Date
Should Investors Be Excited About Sarepta's Delay?
May 25 / MotleyFool.com - Paid Partner Content
Here's Why Sarepta Therapeutics' Stock Is Surging Higher Today
May 25 / MotleyFool.com - Paid Partner Content
Why Computer Sciences, Sarepta Therapeutics, and Nimble Storage Jumped Today
May 25 / MotleyFool.com - Paid Partner Content
Here's Why Sarepta (SRPT) Stock Is Skyrocketing Today
May 25 / TheStreet.com - Paid Partner Content
Sarepta (SRPT) Stock Spikes After FDA Delayed Approval Decision
May 25 / TheStreet.com - Paid Partner Content
A 'What's Next?' Scenario for the Delayed Sarepta Duchenne Drug Review
May 25 / TheStreet.com - Paid Partner Content
Why is Sarepta Therapeutics (SRPT) Stock Soaring 20% Today?
May 25 / Zacks.com - Paid Partner Content
Sarepta Therapeutics (SRPT) Stock Jumps on Possibility of New Drug Approval
May 24 / TheStreet.com - Paid Partner Content
Trending Tickers: SRPT, BABA, CSC, CHK, C
May 25 / TheStreet.com - Paid Partner Content
Forget Sarepta Therapeutics, This DMD Stock Could Be A Better Buy
May 19 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close22.20
Today’s open22.25
Day’s range20.82 - 23.04
Volume6,599,527
Average volume (3 months)5,028,614
Market cap$844.1M
Dividend yield--
Data as of 4:00pm ET, 05/27/2016

Growth & Valuation

Earnings growth (last year)-53.39%
Earnings growth (this year)+12.91%
Earnings growth (next 5 years)+0.37%
Revenue growth (last year)-87.16%
P/E ratioNM
Price/Sales1,302.11
Price/Book4.42

Competitors

 Today’s
change
Today’s
% change
LCILannett Company Inc+0.78+3.40%
RGENRepligen Corp+0.57+2.41%
MGNXMacroGenics Inc+0.55+2.30%
MACKMerrimack Pharmaceut...-0.23-3.52%
Data as of 4:01pm ET, 05/27/2016

Financials

Next reporting dateAugust 4, 2016
EPS forecast (this quarter)-$1.20
Annual revenue (last year)$1.3M
Annual profit (last year)-$220.0M
Net profit margin-17,560.26%

Profile

Sector
Health Technology
Industry
Biotechnology
Senior VP, Chief Executive &
Medical Officer
Edward M. Kaye
Head-Operations &
Vice President
Gavin T. Malenfant
Corporate headquarters
Cambridge, Massachusetts

Forecasts